Eli Lilly CEO: GLP-1 oral pill category is 'expansionary' and is 'not cannibalizing Zepbound'

And I think the best news here about the oral category is it's really expansionary. It's not cannibalizing Zepbound. In fact, Zepbound actually accelerated during these oral launches uh with new starts and our and our market share there.So, um I think the big concern last year from the street was how much growth could there be. Uh is this just a business where people going to cycle on and off the therapies. Is it limited by insurance.I think what we're seeing in the first half of this year and with Lily's r ...